News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
3 Biotechs With Make-or-Break Trial Results, FDA Meetings Coming Soon 9/22/2017
Kymab And Seattle Children's Research Institute Publish Impressive Results Using Kymab’s KY1005 In A Model Of Acute Graft Versus Host Disease (Agvhd) In Science Translational Medicine 9/22/2017
FLX Bio Selects Immuno-Oncology Clinical Candidate 9/21/2017
Sanofi (SNY) And NIH Researchers Develop "Three-In-One" Antibodies As A Potential Breakthrough Intervention For HIV/AIDS 9/21/2017
Audentes (BOLD) Announces Dosing Of First Patient In ASPIRO, A Phase I/II Clinical Trial Of AT132 For The Treatment Of X-Linked Myotubular Myopathy 9/21/2017
Amicus (FOLD) Release: FDA Grants Orphan Drug Designation For ATB200/AT2221 For Pompe Disease 9/21/2017
Roche (RHHBY) Slammed With Partial Holds for Two Combo Cancer Trials 9/20/2017
Protagonist (PTGX) Announces Preliminary Phase I Study Results With Novel Hepcidin Mimetic, PTG-300 9/20/2017
Poxel (POXEL.PA) Announces PXL770 Advances Into A Phase Ib Multiple Ascending Dose Trial 9/20/2017
The Parker Institute For Cancer Immunotherapy And The Cancer Research Institute Announce First Patients Treated In Pancreatic Cancer Clinical Trial Combining Immunotherapy And Chemotherapy 9/20/2017
PharmaMar Starts Clinical Studies With A New Compound –PM14- In Patients With Solid Tumors 9/20/2017
Emerald Health Pharmaceuticals' Scientific Team Leads Cannabinoid Research Showing Potential To Impact Neurodegenerative Diseases 9/20/2017
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cell Freeze Media Embedded In Cellular Biomedicine Group (CBMG) Clinical Trial Of AlloJoin 9/19/2017
Novavax (NVAX) Initiates Phase I/II Trial Of Nanoflu Vaccine In Older Adults 9/19/2017
Imago Biosciences Doses First Patients In Phase I/II Study Of IMG-7289 In Myelofibrosis 9/19/2017
Immuron Highlights Recent Milestones In Quest To Effectively Treat Multiple Forms Of Fatty Liver Diseases That Impact Millions 9/19/2017
TRANSGENE (ENX:TNG): First Patient Treated In A Phase Ib/II Trial Of TG4001 In Combination With Avelumab In HPV-Positive Cancers 9/19/2017
Incysus Submits Investigational New Drug (IND) Application For Allogeneic Gamma-Delta T Cell Immunotherapy For Leukemia And Lymphoma 9/19/2017
TSI Completes Phase I Clinical Trial of Novel Clot-dissolving Therapy, TS01 9/18/2017
Down But Not Out: Juno (JUNO) Preps For Second Round Of CAR-T Cancer War 9/18/2017
Karus Therapeutics Announces First Cancer Patients Dosed With KA2507, A Small Molecule HDAC6-Selective Inhibitor, In A Phase I Clinical Trial 9/18/2017
ZIOPHARM Announces Updated Findings From Phase I Study Of Ad-RTS-Hil-12 + Veledimex In Recurrent Glioblastoma Presented At American Academy Of Neurological Surgery Annual Meeting 9/18/2017
Inovio Pharma (INO) And Partners Initiate Phase I/IIa Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection 9/18/2017
Secretive Moderna Shakes Up R&D Model, Shows Off Early-Stage Trial Data 9/15/2017
FDA Calls Regeneron (REGN), Sanofi (SNY) Carcinoma Drug a Breakthrough 9/15/2017
Levicept Starts First-In-Human Phase I Trial Of LEVI-04, A Novel Fusion Protein Therapy For Chronic Pain 9/15/2017
Emerald Health Pharmaceuticals To Treat Life-Threatening Diseases With Novel Synthetic Cannabinoid-Derived Molecules 9/15/2017
Oncolytics Biotech (ONC.TO) Announces First Patient Treated In MUK Eleven Study 9/14/2017
BriaCell Provides Research Update 9/14/2017
OncBioMune Meets Primary Objective In Trial Of Proscavax Immunotherapy Vaccine For Prostate Cancer 9/14/2017
Imara Reports Favorable Preclinical And Phase I Data On IMR-687 In Sickle Cell Disease 9/14/2017
Mustang Bio Announces Expansion Of CAR T Pipeline Into CD20-Directed Immunotherapies 9/14/2017
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Omaveloxolone For The Treatment Of Malignant Melanoma 9/14/2017
OncoMed (OMED) Doses First Patient With GITRL-Fc In Phase Ia Clinical Trial 9/13/2017
Neuraltus Pharmaceuticals, Inc. And The University of Hawaii At Manoa Announce Initiation Of Phase Ib Study Of NP001 In Patients With Mild-To-Moderate Alzheimer's Disease 9/13/2017
bluebird bio (BLUE) Announces First Patient Treated In Expansion Cohort Of CRB-401, Phase I Study Of Anti-BCMA CAR T Therapy Bb2121 9/13/2017
Eisai Company (ESALY.PK) Presents Results Of Phase Ib/II Clinical Study Of Lenvima (Lenvatinib) In Combination With Pembrolizumab For Renal Cell Carcinoma In Oral Session At ESMO 2017 Congress 9/13/2017
Karolinska Development AB's Portfolio Company Umecrine Cognition Presents Positive Phase Ib Data For Its Drug Candidate Against Hepatic Encephalopathy 9/13/2017
AC Immune SA Completes Recruitment For Low-Dose Cohort In World's First Clinical Trial For Anti-Abeta Vaccine Targeting Alzheimer's Disease-Like Characteristics In Individuals With Down Syndrome 9/12/2017
Nektar (NKTR) Initiates PROPEL Clinical Study To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With TECENTRIQ (Atezolizumab) Or KEYTRUDA (Pembrolizumab) 9/12/2017
BioPharmX Announces Preliminary Data From Rosacea Feasibility Study 9/12/2017
Targovax Announces Start Of Patient Recruitment In Phase I/II Study With ONCOS-102 In Combination With Durvalumab In Patients With Advanced Peritoneal Malignancies 9/12/2017
Patient Dies in Cellectis (CLLS)' Groundbreaking CAR-T Trial, Forcing a Halt to Trials 9/11/2017
CymaBay Therapeutics Granted EMA Orphan Drug Designation For Seladelpar For The Treatment Of Primary Biliary Cholangitis 9/11/2017
Cascadian Therapeutics (ONTY) Release: Tucatinib Data In Multiple Tumor Types Presented At The European Society For Medical Oncology (ESMO) 2017 Congress 9/11/2017
Stemline (STML) Presents SL-801 Phase I Data At ESMO 2017 9/11/2017
ObsEva (OBSV) Announces Presentation Related To Its PGF2alpha Receptor Antagonist At ACCP 2017 Annual Meeting 9/11/2017
Five Prime (FPRX) Announces Updated Data In Mesothelioma Patients From Ongoing Phase Ib Trial Of FP-1039 At ESMO 2017 Congress 9/11/2017
BeiGene (BGNE) Presents Preliminary Phase I Data For BGB-A317 In Multiple Solid Tumors At The ESMO 2017 Congress 9/11/2017
Phosplatin Therapeutics Announces Collaboration With Pfizer (PFE) And Merck KGaA (MKGAF.PK), Darmstadt, Germany To Evaluate Combination Of PT-112 And Avelumab In Phase I / II Studies 9/11/2017
ARMO BioSciences's Phase Ib Trials Demonstrate Continued Promising Response Rates And Survival In Patients With Advanced Pancreatic Cancer, NSCLC, And RCC 9/11/2017
Idera Pharma (IDRA) Presents Positive Phase I Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy 9/11/2017
Eisai Inc. (ESALF.PK) Release: Combination Of Lenvatinib And Pembrolizumab Results In Notable Response Rates For Patients With Advanced Renal Cell Carcinoma Based On Interim Analysis Of Ongoing Phase Ib/II Trial 9/11/2017
Lycera Presents Encouraging Safety Results From Phase I ARGON Study Of LYC-55716 At The European Society For Medical Oncology (ESMO) Congress 9/11/2017
Deciphera Reports Updated Data From Ongoing Phase I Clinical Study Of DCC-2618 At The European Society Of Medical Oncology 2017 Congress 9/11/2017
Zymeworks (ZYME) Presents Additional Safety And Anti-Tumor Activity Data From The Ongoing Phase 1 Study Of ZW25 At The European Society For Medical Oncology 2017 Congress (“ESMO”) 9/11/2017
Blueprint Medicines (BPMC) Announces New Data From Ongoing Phase I Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma 9/11/2017
AmpliPhi Bio (APHB) Announces First Intravenous Treatment Of A Patient With AB-SA01 Targeting Staphylococcus Aureus 9/11/2017
Phase 1 Data For Flotetuzumab, MacroGenics (MGNX)’ CD123 X CD3 DART Molecule, Presented At ESMO Congress 2017 9/11/2017
Ionis Pharma (IONS) Release: New Data Presented At European Society For Medical Oncology Meeting Demonstrate Antitumor Activity With IONIS-STAT3-2.5 Rx In Combination With Imfinzi 9/11/2017
Inovio Pharma (INO)’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise And Significantly Increased PSA Doubling Times In Patients With Recurrent Prostate Cancer 9/11/2017
Checkpoint Therapeutics Receives Orphan Drug Designation For CK-101 For The Treatment Of EGFR Mutation-Positive Non-Small Cell Lung Cancer 9/11/2017
Rexahn Pharmaceuticals, Inc. (RNN) Presents Final Data From The Supinoxin Phase I Clinical Study And New Preclinical Data On RX-3117 At The 2017 European Society For Medical Oncology (ESMO) Congress 9/11/2017
Atara Biotherapeutics (ATRA) Receives Positive Health Canada Regulatory Feedback For ATA129 9/11/2017
FDA Orders 6 Partial or Full Clinical Holds on Celgene (CELG)'s Blood Cancer Studies 9/8/2017
FDA Slaps Partial Hold on 3 of Bristol-Myers Squibb (BMY)'s Opdivo-Based Combo Trials 9/8/2017
Ignyta (RXDX) Announces Presentation Of New Phase IB Clinical Data On RXDX-105 In RET Fusion-Positive NSCLC At ESMO 2017 Congress 9/8/2017
Rafael Pharma (Formerly known as Cornerstone Pharma) To Present Late Breaking Data At The 2017 European Society For Medical Oncology (ESMO) Annual Meeting 9/8/2017
BeiGene (BGNE) Presents Preliminary Phase I/II Clinical Data On PARP Inhibitor BGB-290 In Patients With Advanced Solid Tumors At The European Society For Medical Oncology 2017 Congress 9/8/2017
International Stem Cell Corporation Reports Progress In Phase I Clinical Trial For Parkinson's Disease 9/7/2017
ASLAN Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 9/7/2017
Adamas (ADMS) Announces Topline Phase Ib Data Of ADS-4101 (Lacosamide) For The Treatment Of Partial Onset Seizures In Epilepsy 9/7/2017
Innovate Biopharmaceuticals's Pediatric Ulcerative Colitis Drug Granted Innovate Biopharmaceuticals Orphan Designation 9/7/2017
Argos (ARGS) Announces First Dosing Of HIV Patient With AGS-004 Derived From The Latent Viral Reservoir 9/6/2017
Advanced Accelerator Applications And FUJIFILM RI Pharma Announce First Patient In Bridging Study In Japan For Lutetium Lu 177 Dotatate* (Lutathera) 9/6/2017
Voyager Therapeutics (VYGR) Touts More Gene Therapy Parkinson’s Data 9/6/2017
Sanford Burnham Prebys Medical Discovery Institute And Daiichi Sankyo Announce Enrollment Of First Subject In A Phase I Clinical Trial Of DS-1211 In Healthy Volunteers 9/6/2017
MacroGenics (MGNX) Advances Two First-In-Class Clinical DART Molecules 9/6/2017
Verastem (VSTM) Expands Duvelisib Development Program To Include Peripheral T-Cell Lymphoma 9/6/2017
BioMarin (BMRN) Presents Interim Data Of Phase I/II Study Of BMN 250 For Treatment Of Sanfilippo B Syndrome (MPS IIIB) At 13th International Congress Of Inborn Errors Of Metabolism (ICIEM) 2017 9/6/2017
Catalyst Biosciences Announces Positive Factor IX Clinical Data 9/6/2017
Global Blood Therapeutics (GBT) To Convene Sickle Cell Disease Influencers At Annual Sickle Cell Disease (SCD) Therapeutics Conference 9/6/2017
Sarepta (SRPT) Announces Positive Results In Its Study Evaluating Gene Expression, Dystrophin Production, And Dystrophin Localization In Patients With Duchenne Muscular Dystrophy (DMD) Amenable To Skipping Exon 53 Treated With Golodirsen (SRP-4053) 9/6/2017
Aeglea (AGLE) Doses Two Patients In Repeat Dose Part Of Phase I/II Clinical Trial For The Treatment Of Arginase 1 Deficiency 9/6/2017
Sanofi (SNY) Quietly Ends Its Zika Vaccine Project 9/5/2017
ProQR Therapeutics (PRQR)’s Drug Candidate QRX-421 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA 9/5/2017
Biocryst (BCRX) Announces Positive Results From Its Apex-1 Phase II Trial In HAE 9/5/2017
Deciphera Announces FDA Orphan Drug Designation For DCC-2618 For The Treatment Of Glioblastoma Multiforme And Anaplastic Astrocytoma 9/5/2017
EnGeneIC Pty Ltd Announces Publication In The Lancet Oncology Of First Clinical Study Employing EDV Nanocell Platform to Enable microRNA Replacement Therapy 9/5/2017
H3 Biomedicine Announces First Patient Dosed With H3B-6545 In Phase I Study In Breast Cancer 9/5/2017
Thiel-Backed Biotech Rational Vaccines Will Follow FDA Guidelines After Offshore Trial Controversy 9/5/2017
CytoSorbents Highlights Important Research Advances In Traumatic Brain Injury, Hemorrhagic Shock, And Severe Hyperkalemia At The Military Health System Research Symposium 9/5/2017
Atara Biotherapeutics (ATRA) Receives FDA Orphan Drug Designation For ATA230 9/5/2017
Aelix Therapeutics Enrolls First Patient In Company’s Initial Therapeutic HIV Vaccine Clinical Trial 9/5/2017
Investors Wait with Bated Breath for AstraZeneca PLC (AZN)'s Cancer Trial Data Next Week 9/1/2017
Incyte (INCY) Discloses Promising New Data in Combo Drug Trial With Merck & Co. (MRK)'s Keytruda 9/1/2017
Heptares Release: First Subject Dosed In Phase I Clinical Study Of Novel Selective MUSCARINIC M4 Agonist In Development To Treat Major Symptoms Of Alzheimer's Disease 9/1/2017
Sosei: First Subject Dosed In Phase1 Clinical Study Of Novel Selective Muscarinic M4 Agonist In Development To Treat Major Symptoms Of Alzheimer's Disease 9/1/2017
Aquavit Pharmaceuticals's iMicrotox (IMX-001) Study Receives IRB Approval 9/1/2017
X4 Pharma Release: First Data From Combination Of X4P-001-IO And Inlyta (Axitinib) In Patients With Clear Cell Renal Cell Carcinoma Will Be Presented At The European Society Of Medical Oncology 2017 Congress 8/31/2017
Bristol-Myers Squibb (BMY) Data At ESMO 2017 Demonstrate Company’s Innovative Research Approach To Treating Cancer From All Angles 8/31/2017
Immune Design Corporation (IMDZ) Announces New CMB305 + Checkpoint Inhibitor Topline Data From An Upcoming Presentation At The ESMO 2017 Congress 8/31/2017
Dimension Therapeutics (DMTX) Commences Patient Dosing In Global, Multi-Center Phase I/II Clinical Trial Of DTX301 In Ornithine Transcarbamylase (OTC) Deficiency 8/31/2017
Protalex (PRTX) Doses First Patient In Third Cohort Of European Phase Ib Study Of PRTX-100 In ITP 8/29/2017
Future Unclear For Merck & Co. (MRK)'s Cholesterol Drug As Trial Data Underwhelms 8/29/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase I Clinical Trial Of Selective PI3Kd Inhibitor HMPL-689 In Lymphoma Patients In China 8/29/2017
ProQR Therapeutics (PRQR) Completes Dosing Of Cystic Fibrosis Patients In QR-010 Phase Ib Trial 8/29/2017
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation For EB-101 Autologous Cell Therapy In Epidermolysis Bullosa 8/29/2017
Biogen (BIIB) Shows Off More Positive Alzheimer’s Trial Data 8/29/2017
Big-Name Investor Peter Thiel Funds ‘Unethical’ Offshore Herpes Vaccine Trial 8/28/2017
How A Potential Drug And A Possible M&A Could Drive Exelixis (EXEL) Even Higher 8/28/2017
Tesaro (TSRO) Announces Nine Data Presentations At The 2017 European Society For Medical Oncology (ESMO) Annual Meeting 8/25/2017
Celsion (CLSN) Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference 8/24/2017
CURE Pharma Subsidiary, Oak Therapeutics, Completes Critical Milestone In Phase I Of NIH Grant To Develop Oral Dissolvable Strip For Tuberculosis 8/23/2017
Unum Announces Active Investigational New Drug (IND) Application For ACTR087 In Combination With SEA-BCMA In Patients With Relapsed/Refractory Multiple Myeloma 8/23/2017
Asterias Biotherapeutics Opens Additional Clinical Site For AST-OPC1 Scistar Study 8/23/2017
Function Of Cognition Therapeutics’ Neurological Drug Screening Platform Presented At American Chemical Society National Meeting 8/23/2017
Blueprint Medicines (BPMC) To Present Updated Data From Ongoing Phase I Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma At ESMO 2017 Congress And 11th ILCA Annual Conference 8/22/2017
PharmAkea Announces Successful Completion Of A Phase I Trial In Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-1251 8/22/2017
Humanetics To Present Data At Department Of Defense Scientific Meeting 8/22/2017
Phase I Trials For Two Novel Treatments Of Obesity And/Or Diabetes Initiated By Zealand Pharma  (ZEAL.CO) Partner Boehringer Ingelheim 8/22/2017
Cellectar Biosciences  (CLRB) Announces Significant PDC Platform Advancement; Demonstrates Potential To Improve Therapeutic Window 8/22/2017
TrovaGene (TROV)'s PLK1 Inhibitor PCM-075 Demonstrates Synergy With A HDAC Inhibitor In Non-Hodgkin Lymphoma Cell Lines 8/21/2017
Boehringer Ingelheim: Advancing Anticoagulation Care With New Data At ESC Congress 2017 8/21/2017
Ovid Technologies Announces First Patient Randomized In Phase Ib/IIa Clinical Trial Of TAK-935/OV935 In Adults With Rare Epilepsies 8/21/2017
Cellectis (CLLS)’ UCART123 Administered To First Patient With BPDCN In Phase I Clinical Trial At MD Anderson Cancer Center 8/18/2017
Kite Pharma (KITE) Highlights Publication From The NCI Demonstrating Responses In Patients With Metastatic Solid Tumors Treated With T Cell Receptor (TCR) Therapy Targeting MAGE A3 8/17/2017
Biogen (BIIB) Gained $1 Billion Overnight After Becoming Goldman Sachs' Favorite Biotech 8/17/2017
PolyPid Ltd. Completes Enrollment In Phase Ib/II Study Of D-PLEX In Post-Cardiac Surgery Sternal Infection 8/16/2017
TRACON Pharma (TCON) Announces Positive Results From NCI Phase I/II Trial Of TRC105 And Nexavar In Hepatocellular Cancer Published In Clinical Cancer Research 8/16/2017
U.S. Department Of Defense To Conduct Studies Of Pluristem Therapeutics (PSTI)’s PLX-R18 In A New ARS Project For Use Before Radiation Exposure 8/16/2017
CoCrystal Announces Positive Data From The Successful Completion Of Phase 1a/1b Trial Of The Non-Nucleoside Polymerase Inhibitor CC-31244 For The Treatment Of Chronic Hepatitis C Infection 8/15/2017
H3 Biomedicine Granted Orphan Drug Designation Of H3B-8800 For Treatment Of Acute Myelogenous Leukemia And Chronic Myelomonocytic Leukemia 8/14/2017
Hemispherx (HEB) Human Safety Study Of Intranasal Ampligen With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated 8/14/2017
CARsgen Therapeutics Launches First-In-Class Anti-Claudin18.2 CAR-T Clinical Trial 8/10/2017
KemPharm (KMPH) Announces Preliminary Results From KP415 Pharmacokinetic Single And Multiple Dose Trial 8/10/2017
Sun BioPharma Files Form 10-Q For Second Quarter 2017 And Provides Clinical Update 8/10/2017
Asterias Biotherapeutics Enrolls First Patient in Final Cohort of SCiStar Clinical Trial 8/9/2017
Theravance Biopharma (TBPH) Reports Encouraging Data From First Cohort Of Patients In Phase Ib Clinical Trial Of TD-1473 In Ulcerative Colitis 8/9/2017
Cellectar Biosciences  (CLRB)’ CLR 131 Achieves Overall Survival Of Greater Than 22 Months In Advanced Multiple Myeloma Patients 8/8/2017
Selvita And The Leukemia & Lymphoma Society Announce Partnership To Advance SEL120 Into Phase I For AML Patients 8/8/2017
How To Try An Experimental Drug When You Don't Qualify For A Clinical Trial 8/8/2017
Verona Pharma (VRP.L) Interim Results For The Six Months Ended June 30, 2017 And Clinical Development Update 8/8/2017
Mitobridge’s Novel Treatment Approach For Duchenne Muscular Dystrophy Advances Into Clinical Development 8/8/2017
Novogen (NVGN) Release: Progress Update On Cantrixil (TRXE-002-1) Development 8/7/2017
Generex Biotechnology Corporation (GNBT) Provides Summary Of Ii-Key Hybrid Vaccine Platform 8/7/2017
4 Clinical Projects Shelved From Pfizer (PFE)’s Pipeline 8/3/2017
Spark Therapeutics (ONCE) Unveils Encouraging Hemophilia A Data 8/3/2017
Intec Pharma Reports Clinical Results From Phase I Trial Of Accordion Pill For Cannabinoid Therapies 8/3/2017
Asterias Biotherapeutics Opens Two Additional Clinical Sites For AST-OPC1 SCiStar Study 8/3/2017
DARA BioSciences Discusses Key Goals With Wall Street Analyzer 8/3/2017
Following Recent Death, InVivo Therapeutics (NVIV) Temporarily Halts Enrollment in INSPIRE Study 8/2/2017
Aprea Announces First Patient Enrolled In Phase Ib/II Clinical Study Of APR-246 For The Treatment Of Platinum-Resistant High-Grade Serous Ovarian Cancer 8/2/2017
Bolder BioTechnology, Inc. Announces Initiation Of Phase I Clinical Trial Of BBT-015 For Treating Neutropenia And Acute Radiation Syndrome 8/2/2017
Celsion (CLSN) Announces Latest Translational Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients 8/2/2017
Madison Vaccines Announces First Patient Dosed In An Expanded Combination Trial Of MVI-816 Plus Keytruda® For Metastatic, Treatment-Resistant Prostate Cancer 8/2/2017
Aridis Pharma Enrolls First Patients In Global Pivotal Clinical Trial Of Novel Monoclonal Antibody For Treating Acute Pneumonia 8/2/2017
Massachusetts’ Homology Medicines Snags $83.5M to Advance AMEnDR into Human Trials 8/1/2017
First Human Subject Enrolled In Lumosa (6535.TWO)' LT3001 Trial 8/1/2017
NantKwest Announces Durable Complete Responses In Ph1 Trial Of Ank Cell Therapy In Patients With Relapsed Hematological Malignancies 8/1/2017
Amygdala Initiates Phase Ib Clinical Study Of ANS-6637, The First-In-Class Selective ALDH2 Inhibitor In Development As A Treatment For Substance Use Disorder 8/1/2017
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases 8/1/2017
Proteostasis (PTI) Announces Progression Of PTI-428 And PTI-801 To Longer Duration Studies In CF Subjects 8/1/2017
ViaCyte Announces First Patients Implanted With PEC-Direct Islet Cell Replacement Therapy In International Clinical Trial 8/1/2017
FDA Calls Roche (RHHBY)'s Leukemia Drug a Breakthrough 7/31/2017
Intercept Pharma (ICPT) Release: CONTROL Trial Shows Statin Therapy Reversed LDL Increases To Below Baseline Levels In NASH Patients Treated With OCA 7/31/2017
Mateon Therapeutics (MATN) Announces Positive Initial Data From Fifth Cohort Of Phase Ib Study Of Oxi4503 In Relapsed/Refractory AML 7/31/2017
Zosano (ZSAN) Announces Publication F Positive Phase I Data Of Zolmitriptan Delivery In Future Medicine’s Pain Management Journal 7/31/2017
Kymab Announces Clinical Update On Its Promising New Antibody KY1005 For Treatment Of Autoimmune Diseases 7/31/2017
Amgen (AMGN) Falls After Earnings Update Reveals Embarassingly 'Bare' Pipeline 7/27/2017
Drinking Alcohol After Studying Can Improve Memory, Scientific Reports Reveals 7/27/2017
TrovaGene (TROV) Announces FDA Approval Of IND For Phase Ib/II Trial Of PCM-075 In Patients With Acute Myeloid Leukemia 7/27/2017
NewLink Genetics (NLNK) Announces First Patient Dosed In Phase I Study Of IDO Pathway Inhibitor NLG802 7/27/2017
Seattle Children's Research Institute's Opens CD22 CAR T-Cell Immunotherapy Trial For Children And Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy 7/27/2017
Eli Lilly (LLY) Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs 7/26/2017
2 Tiny Cancer Biotechs That Could Gain Steam by Year-End 7/26/2017
BioPharm Executive: And So It Continues: Let's Get Rid of Clinical Trials (Part 2) 7/26/2017
CureVac Announces Publication In The Lancet Of First-Ever Human Proof-Of-Concept Study Investigating The Safety And Immunogenicity Of A Prophylactic mRNA Vaccine 7/26/2017
Sequoia Sciences, Inc. Receives FDA Fast Track Designation For Vaccine For Urinary Tract Infections Caused By Multidrug-Resistant Bacteria 7/26/2017
Oncolytics Biotech (ONC.TO) To Present REOLYSIN Safety Data In Combination With Chemotherapy At ESMO 2017 Congress 7/26/2017
First Patient Enrolled In Oncoquest's Phase I/II Study Combining Oregovomab With Hiltonol In Recurrent Ovarian Cancer 7/26/2017
Argos (ARGS) Reports Immunogenicity Results Of AGS-004 In HIV Program 7/26/2017
5 Biotechs With $45 Billion Worth of Not-Yet Approved Drugs in the Pipeline 7/25/2017
TrovaGene (TROV) Announces Peer-Reviewed Publication Of First-In-Human Phase I Trial Results With PCM-075, Its Polo-Like Kinase 1 (PLK1) Inhibitor 7/25/2017
Kezar Life Sciences Announces Successful Completion Of Phase Ia Study And Secures $50 Million In Series B Financing 7/25/2017
AntriaBio Announces First Patient Dosed In Phase I Clinical Study Of AB101 7/25/2017
Q Therapeutics, Inc. Release: FDA Allows Q-Cells For First-In-Human Transverse Myelitis Trial 7/25/2017
Axsome (AXSM) Announces AXS-06 (Moseic Meloxicam And Esomeprazole) Meets Primary Endpoint In Phase I Clinical Trial 7/25/2017
Atossa Genetics (ATOS) Completes Enrollment In Endoxifen Phase I Study And Provides Update On Fulvestrant Microcatheter Phase II Study 7/25/2017
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer 7/24/2017
ORYZON Genomics Presents Final Data On The Phase I Trial With ORY-2001 At The Alzheimer's Association International Conference (AAIC-2017) 7/24/2017
NovoCure Announces A Phase Ib Clinical Trial To Evaluate The Safety Of Marizomib And Temozolomide In Combination With Optune® As Adjuvant Therapy In Patients With Glioblastoma 7/24/2017
Johnson & Johnson (JNJ) Announces Encouraging First-In-Human Clinical Data For Investigational HIV Preventive Vaccine 7/24/2017
BioLight Life Sciences Reports Successful Results In Phase I/IIa Clinical Trial For Glaucoma Insert 7/24/2017
Valneva Receives FDA Fast Track Designation For Its Lyme Disease Vaccine Candidate VLA15 7/24/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
uniQure (QURE) Announces The Successful Development And Scale-Up Of Manufacturing Processes For Its Hemophilia B Gene Therapy Program 7/21/2017
Vertex (VRTX) Gains $8 Billion Overnight as Cystic Fibrosis Combo Drug Wows in Trials 7/21/2017
Kite Pharma (KITE) Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy 7/21/2017
Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space 7/20/2017